Shattuck Labs, Inc.
Shattuck Labs, Inc. (STTK): 6 pipeline candidates · 1 upcoming catalyst · ~20 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
20.4 months
D/E 0.07 · 48% dilution
Lead: Phase 1
6 candidates
1 upcoming, next in ~743d
0 buys · 2 sells (180d)
A transparent, data-derived signal for Shattuck Labs, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$416.4M
Cash
$90.4M
Quarterly Burn
$13.4M
Runway
20.4 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
Upcoming Catalysts (1)
Frequently asked questions
How many drug candidates are in Shattuck Labs, Inc.'s pipeline?
Shattuck Labs, Inc. (STTK) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Shattuck Labs, Inc.'s lead drug candidate?
Shattuck Labs, Inc.'s most advanced tracked candidate is mirvetuximab + sl-172154 (Phase 1) for Platinum-resistant Ovarian Cancer.
What is Shattuck Labs, Inc.'s next catalyst?
Shattuck Labs, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: sl-325" — expected June 30, 2028.
What is Shattuck Labs, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Shattuck Labs, Inc. has approximately 20.4 months of cash runway.
What is Shattuck Labs, Inc.'s market capitalization?
Shattuck Labs, Inc.'s market capitalization is approximately $416.4M.
Get the full picture on Shattuck Labs, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.